General MedicationsINTRAMUSCULARStandard

INVEGA TRINZA

PALIPERIDONE PALMITATE

Standard Dose

273MG/0.875ML (273MG/0.875ML)

Max Dose

Refer to approved labeling

Primary Use

Review priority: STANDARD Marketing status: Prescription

Summary

Approval overview INVEGA TRINZA is listed in Drugs@FDA under application 207946 (NDA).

Review priority: STANDARD Marketing status: Prescription Active ingredient PALIPERIDONE PALMITATE Form and strength SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR - 273MG/0.875ML (273MG/0.875ML) Sponsor JANSSEN PHARMS Submission history Latest submission status date: 2025-01-23 00:00:00.

Structured Monograph

Clinical summary

Approval overview INVEGA TRINZA is listed in Drugs@FDA under application 207946 (NDA). Review priority: STANDARD Marketing status: Prescription Active ingredient PALIPERIDONE PALMITATE Form and strength SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR - 273MG/0.875ML (273MG/0.875ML) Sponsor JANSSEN PHARMS Submission history Latest submission status date: 2025-01-23 00:00:00. Submission type: SUPPL.

Monitoring

• Marketing status: Prescription
• Review priority: STANDARD

Interaction Notes

No interaction notes stored yet.